Increasing Prevalence of Muscular Dystrophy to Augment the Muscular Dystrophy Treatment Market Growth

 


Muscular dystrophy is a common disease that causes muscles to become weaker and unable to continue to develop properly. Because it often affects young children as well as adults, it can be difficult to detect. However, once symptoms are noticed, steps must be taken to prevent the disease. There are many treatment options available for muscular dystrophy. The severity of the disease will determine what type of treatment is best for your situation. Muscular dystrophy treatment involves breathing aids, therapy, surgery, or medication, which may help maintain function, but life span is often shortened.

Market Dynamics:

Increasing prevalence or incidence of muscular dystrophy, especially in the North America, is expected to propel the growth of the muscular dystrophy treatment market. For instance, one in 3,500 male babies born worldwide are affected with Duchenne muscular dystrophy (DMD), according to the National Organization for Rare Disorders. Moreover, in 2019, around 349 new cases of Duchenne muscular dystrophy (DMD) were reported in United States, according to Centers for Disease Control and prevention (CDC).

Moreover, increase in the number of clinical trials for testing the future treatment for DMD and increasing investments to find out effective treatment for DMD are expected to augment the growth of the muscular dystrophy treatment market. For instance, in February 2021, Parent Project Muscular Dystrophy (PPMD) announced a US$ 1 million investment in Satellos Bioscience to support the development of a technology that aims to repair and regenerate muscle cells in people with Duchenne muscular dystrophy (DMD).

Increasing research and development activities are also expected to fuel the growth of the muscular dystrophy treatment market. For instance, in September 2020, a research team from the Yale University identified a possible treatment for DMD, by targeting an enzyme that had been considered undruggable. However, the high cost of treatment and lack of awareness among people is expected to restrain the growth of the muscular dystrophy treatment market.

Competitive Analysis:

Major players active in the muscular dystrophy treatment market are Eli Lilly, Pfizer, Lexicon Pharmaceuticals, Bristol-Myers Squibb, Capricor Therapeutics, BioMarin Pharmaceutical, PTC Therapeutics, Acceleron Pharma, Sarepta Therapeutics, and Santhera Pharmaceuticals.

Major players in the market are focused adopting various strategies, such as product launch, to expand their product portfolio. For instance, in 2019, Sarepta Therapeutics received the Food and Drug Administration (FDA) approval for VYONDYS 53 (golodirsen) injection for the treatment of Duchenne muscular dystrophy (DMD).


Comments

Post a Comment

Popular posts from this blog

Increasing Consumption and Production of Fertilizers to Upsurge the Growth of the Agrochemicals Market

Image
  Agrochemical products are those chemicals that are used to increase the production of an agricultural environment. Agrochemical chemicals typically include pesticides, fertilizers, lime precursors, acidizing and alkalizing agents (all of which are designed to alter the normal pH level of the soil), lime stabilizers, and other nutrients that are required for plant growth. These chemicals are widely used by farmers and are crucial to the functioning of modern agriculture. The use of these chemicals presents a number of concerns both from the perspective of the environment and the human body. The increasing need for improving crop production due to the growing concern of food security and lack of arable land is fueling the growth of agrochemicals market . Growing advancement in technology is raising adoption of advanced and sustainable farming practices which is again propelling the growth of the market. The increasing population coupled with the growing usage of fertilizers around th
Read more

High Prevalence of Cancer and R&D in Anti-Cd39 Antibodies to Augment Growth of Anti-body Coupled T Receptor Therapy Market

Image
  Antibody-Coupled T cell Receptor (ACTR) is an autologous engineered T cell therapy that combines the Fc receptor, CD16, with endogenous T cell signaling and costimulatory domains. It is combined with tumor-targeting antibodies to exert potent anti-tumor immune responses and eliminate cancerous cells. ACRT has demonstrated potential in the treatment of multiple myeloma and HER2+ advanced cancers. Market Dynamics R&D in anti-CD39 antibodies is expected to propel growth of the Anti-body Coupled T Receptor Therapy Market . For instance, in December 2020, Arcus Biosciences, Inc. expanded its existing partnership with WuXi Biologics, a developer of biologics technology platforms, for R&D in anti-CD39 antibodies using WuXi Bio’s proprietary technology. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 canc
Read more